Patent · US Active

Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension

US7674921B2 · kind B2 · utility

2Cited by

2References

4Claims

0Family size

Assignee

CAYMAN CHEMICAL COMPANY, INC. · US

Inventors

Kirk M. Maxey · Ann Arbor, US
Michelle L. Stanton · Ann Arbor, US

Key dates

Filing date	Feb 25, 2008
Grant date	Mar 9, 2010
Priority date	—
Expiry date	Feb 25, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D327/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction of ocular hypertension.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.